Q Fever
10
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Q Fever and Auto-immunity
The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment
Safety Evaluation of a Q-fever Vaccine, NDBR 105
Safety and Immunogenicity of Q Fever Vaccine
Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France
Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island
Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)
A Screening Strategy for Q Fever Among Pregnant Women